drugset / Trial / NCT06223984

Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients

NCT06223984

Phase 4 Completed 178 enrolled Konya City Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

In December 2019, SARS-COV-2 was isolated from patients for the first time . It then rapidly turned into a pandemic affecting the whole world.While most Covid patients survive the disease with mild symptoms, some may develop severe organ failure and respiratory failure requiring mechanical ventilation. COVİD-19 pneumonia may progress into acute respiratory distress syndrome (ARDS). The most important reason for this has been shown in studies; is thought to be because a group of patients develop a cytokine storm-associated hyperinflammatory state characterized by features of macrophage activation syndrome (MAS). The aim of this study was to evaluate the clinical outcomes of the combined use of pulse steroid and intravenous immunoglobulin therapy in patients with severe COVID-19 with severe respiratory distress in intensive care unit.

Timeline

Start
2020-03-30
Primary completion
2020-11-14
Completion
2020-11-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Immune Globulin Intravenous (Human) Protein / enzyme biologic 400 mg/kg Intravenous
Comparator Methylprednisolone Other / unclassified 250 mg

Indications

No indication recorded.